1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  

This page is powered by Blogger. Isn't yours?

Tuesday, June 21, 2016

 

Memory loss in early Alzheimer's reversed with personalized treatment plan
































Image Source: DREAMSTIME

Researchers have successfully reversed memory loss in a small number of people with early-stage Alzheimer's disease using a comprehensive treatment program, which involves a combination of lifestyle changes, brain stimulation, and medication.

Researchers suggest the MEND program is highly effective for reversing memory loss.Memory improvements as a result of the treatment program have so far been sustained for 2 years, the researchers report, and some patients have even been able to return to work as a result.

Study co-author Dr. Dale Bredesen, of the Buck Institute on Research and Aging in Novato, CA, and colleagues recently published their findings in the journal Aging.

While the study only involved 10 patients, the researchers believe their findings may open the door to an effective therapy for cognitive decline.

"The magnitude of improvement in these 10 patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective," says Dr. Bredesen.

There are currently around 5.4 million people in the United States living with Alzheimer's disease.

It is estimated that by 2050, around 13.8 million Americans will have the condition - a dramatic increase that highlights the need for prevention and treatment strategies.

Unfortunately, identifying such strategies has proven challenging for researchers; while certain treatments have demonstrated effectiveness against cognitive decline in animal models, few show efficacy in humans.

In this latest study, Dr. Bredesen and colleagues suggest that a more personalized, combined treatment approach to cognitive decline may be the way forward.

The MEND program
The team - including researchers from the University of California-Los Angeles - assessed the effects of a treatment program called metabolic enhancement for neurodegeneration (MEND) on 10 patients.

The program - which is adapted to each individual patient - is described as a "36-point system" that involves changes in diet, exercise, sleep optimization, the use of specific medications and vitamins, and brain stimulation.

"Imagine having a roof with 36 holes in it, and your drug patched one hole very well - the drug may have worked, a single 'hole' may have been fixed, but you still have 35 other leaks, and so the underlying process may not be affected much," explains Dr. Bredesen.

"We think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well."

All patients included in the study were experiencing memory loss as a result of mild cognitive impairment (MCI), subjective cognitive impairment (SCI), or early-stage Alzheimer's disease.

The team notes that nine of the patients possessed the ApoE4 gene, putting them at increased risk for Alzheimer's disease; five of the patients had two copies of this gene, meaning they were 10 to 12 times more likely to develop the condition.

The patients underwent cognitive testing before and after being treated with the MEND protocol.

'Far-reaching implications' for treatment of memory loss
The researchers found all 10 patients showed significant long-term improvements in memory with MEND, with many of the patients moving from "abnormal" to "normal" cognitive function.

One patient - a 69-year-old man who was in the process of shutting down his business after 11 years of progressive memory loss - saw major improvements in memory after just 6 months of MEND, such as the ability to recognize faces at work and remember his schedule.

After 22 months of treatment, his long-term memory recall increased from 3 percent to 84 percent, the researchers report. Now, instead of shutting down his business, he is expanding it.

Another case involved a 49-year-old woman who had major problems with facial recognition and verbal memory. Within a few months of treatment with MEND, she experienced significant improvements, such as regaining the ability to speak a foreign language.

One other patient was a 66-year-old man who had MCI. From magnetic resonance imaging (MRI) scans, the team found that he showed an almost 12-percent increase in volume in the hippocampus - a brain region important for memory and learning.

Overall, the researchers believe their findings indicate that the MEND program may be an effective way to reverse memory loss in patients with early cognitive decline - even those who have a genetic risk for the condition.

The team adds:

"These results have far-reaching implications for the treatment of Alzheimer's disease, MCI, and SCI; for personalized programs that may enhance pharmaceutical efficacy; and for personal identification of ApoE genotype."

While the results are promising, the researchers stress that studies involving a larger number of participants are needed in order to confirm the benefits of MEND for memory loss.

Written by Honor Whiteman

Story Source: The above story is based on materials provided by MEDICALNEWSTODAY
Note: Materials may be edited for content and length